https://news.harvard.edu/gazette/story/2020/08/cheap-daily-covid-tests-could-be-akin-to-vaccine/
A Harvard epidemiologist and expert in disease testing is calling for a shift in strategy toward a cheap, daily, do-it-yourself test that he says can be as effective as a vaccine at interrupting coronavirus transmission — and is currently the only viable option for a quick return to an approximation of normal life.
As the pandemic’s health, economic, and educational toll mounts, Mina, a member of the Harvard Chan School’s Center for Communicable Disease Dynamics, said the paper-strip tests have already been developed and their shotgun approach to testing — cheap and widespread — provides a way back to the workplace, classroom, and other venues.
The strategy, if adopted and backed by the federal government, could put hundreds of millions of tests in the hands of consumers within weeks, at a cost far less than repeated rounds of economic stimulus, Mina said. The tests, which can be produced for less than a dollar, can be performed by consumers each day or every other day. Though not as accurate as current diagnostic tests, they are nonetheless effective at detecting virus when a person is most infectious, Mina said. If everyone who tests positive stays home, he said, the widespread effect would be similar to that of a vaccine, breaking transmission chains across the country.
Several hurdles stand in the way for widespread dissemination of the tests, Mina said. Perhaps the largest hurdle is regulatory. The Food and Drug Administration, in charge of approving diagnostic tests, has held up approval because the tests aren’t as accurate as nasal-swab, lab-based tests. While that would matter if they were intended as an individual diagnostic tool, Mina said that from a public health viewpoint, they are accurate enough to provide critical initial screening on a large scale. Positive test results could be followed up by a visit to the doctor and a more accurate nasal swab test or, if illness weren’t that severe, by daily testing until a person is negative.
“Everyone says, ‘Why aren’t you doing this already?’ My answer is, ‘It is illegal to do this right now,’” Mina said. “Until the regulatory landscape changes, those companies have no reason to bring a product to market.”
Mina said he’s concerned that approval will be contingent on making the tests closer to the accuracy of PCR (polymerase chain reaction) tests, which will likely add enough cost to short-circuit their widespread use, and their usefulness as a vehicle to interrupt the course of the pandemic.
———————
This was published over 10 weeks ago. I don’t follow the COVID news as closely as most here, but in the last 10 weeks I’ve seen a lot about spikes in cases all over the country, rollbacks of openings of our economies and schools, increases in lockdown measures, and nothing about clearing FDA regulatory hurdles to offer us a potential solution that is dramatically cheaper.